What is the recommended dose of colistin (polymyxin E) for an adult patient with normal renal function?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 7, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Recommended Colistin Dosing for Adults with Normal Renal Function

For adult patients with normal renal function, colistin should be administered with a loading dose of 9 million international units (MIU) followed by a maintenance dose of 4.5 MIU every 12 hours (9 MIU/day). 1

Dosing Regimen

  • A loading dose of 9 MIU is critical to rapidly achieve therapeutic levels due to colistin's relatively long half-life in relation to dosing intervals 1, 2
  • For maintenance therapy in patients with normal renal function (creatinine clearance ≥80 mL/min), the recommended dose is 4.5 MIU every 12 hours 1, 2
  • Alternative weight-based dosing is 2.5-5 mg/kg/day divided into 2-4 doses 1, 3
  • In obese individuals, dosing should be based on ideal body weight rather than actual body weight 3

Administration Methods

  • Colistin should be administered as a slow intravenous infusion over 3-5 minutes for direct intermittent administration 3
  • A 4-hour infusion is suggested to optimize pharmacokinetic/pharmacodynamic properties 1
  • For continuous infusion, administer half the daily dose over 3-5 minutes, then the remaining half over the next 22-23 hours 3

Important Considerations

Dosing Units and Conversions

  • Colistin is administered as colistimethate sodium (CMS), an inactive prodrug 1
  • One million IU of colistin is equivalent to 80 mg of CMS 1
  • The FDA label indicates that a 150 mg vial should be reconstituted with 2 mL Sterile Water for Injection to provide a concentration equivalent to 75 mg/mL colistin base activity 3

Monitoring and Safety

  • Renal function should be closely monitored during colistin therapy as acute kidney injury is a significant risk factor for clinical failure and mortality 1
  • Nephrotoxicity typically develops within 3.8 ± 0.8 days of starting colistin therapy 4
  • Higher daily doses (≥300 mg) are associated with increased risk of nephrotoxicity 4, 5
  • Colistin is significantly more nephrotoxic than Polymyxin B (39.3% vs 11.8% nephrotoxicity rate) when administered in currently recommended doses 4

Special Considerations

  • For critically ill patients with severe sepsis/septic shock, high extended-interval maintenance doses (4.5 MIU every 12 hours) are recommended 2
  • Patients with augmented renal clearance (ARC) may receive standard doses but might require longer duration of therapy 6
  • For patients with impaired renal function, the maintenance dose should be individually adjusted according to creatinine clearance 7
  • For patients on continuous renal replacement therapy, a dose of at least 9 MIU/day is recommended 7, 2

Limitations of Current Dosing Recommendations

  • For patients with creatinine clearance ≥80 mL/min, even maximum allowed daily doses may not achieve target plasma concentrations in all patients 8
  • Pharmacokinetic studies show wide inter-individual variation in colistin parameters, which may affect optimal dosing 9
  • The recommended dose may be inadequate to maintain optimal C(max)/MIC ratios for certain pathogens, particularly Pseudomonas species 9

References

Guideline

Colistin Dosage Guidelines for Patients with Normal Renal Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Colistin Dosage Administration in Patients with Impaired Renal Function

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Dosing guidance for intravenous colistin in critically-ill patients.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2017

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.